Matches in SemOpenAlex for { <https://semopenalex.org/work/W2179662562> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2179662562 endingPage "547" @default.
- W2179662562 startingPage "546" @default.
- W2179662562 abstract "Even though current antiviral treatments based on pegylated interferon, or nucleos(t)ide analogues, in mono or combination therapies, have demonstrated clinical benefit to HBV-infected patients, chronic hepatitis B remains a difficult-to-cure disease. An absolute cure, defined as total elimination of HBV DNA, is currently not achievable, and a functional cure characterised by sustained virological response and HBV surface antigen (HBsAg) clearance off-treatment remains a challenge. Pegylated interferon treatment can lead to a sustained virological response and HBsAg clearance off-treatment in only 3–7% of patients,1 and it is too often associated with contraindications and adverse effects. Long-term treatment with nucleos(t)ide analogues is better tolerated, but the chance to achieve a sustained virological response and HBsAg loss remains low,2 and the drugs do not eradicate intrahepatic HBV DNA.The risk of disease progression and development of hepatocellular carcinoma in chronically HBV-infected patients is clearly associated with high levels of serum HBV DNA and HBsAg.3 ,4 Since high levels of serum HBsAg may be responsible for exhaustion of HBsAg-specific T-cell response in chronically infected individuals, an antiviral strategy aimed at suppressing circulating HBsAg could restore virus-specific immune response and promote viral clearance.5Zhang et al 6 investigated the potential of anti-HBsAg monoclonal antibodies (mAbs) infusion for clearance of circulating HBsAg in chronic infection. The study was based on (i) the previous observation that anti-HBsAg mAbs treatments could have short-term antiviral effects,7 ,8 and (ii) the growing interest in mAbs-based immunotherapy for viral diseases, including infections with HIV, HCV and Ebola virus.9 The therapeutic use of antiviral mAbs was initially based on the mAbs activity in virus neutralisation …" @default.
- W2179662562 created "2016-06-24" @default.
- W2179662562 creator A5056297092 @default.
- W2179662562 date "2015-11-26" @default.
- W2179662562 modified "2023-09-24" @default.
- W2179662562 title "A unique monoclonal antibody for therapeutic use against chronic hepatitis B: not all antibodies are created equal" @default.
- W2179662562 cites W1975960076 @default.
- W2179662562 cites W2002144368 @default.
- W2179662562 cites W2002969023 @default.
- W2179662562 cites W2047043751 @default.
- W2179662562 cites W2052217197 @default.
- W2179662562 cites W2066286787 @default.
- W2179662562 cites W2074983991 @default.
- W2179662562 cites W2102978702 @default.
- W2179662562 cites W2103863790 @default.
- W2179662562 cites W2131134210 @default.
- W2179662562 cites W2140038670 @default.
- W2179662562 cites W2147647823 @default.
- W2179662562 cites W2148216588 @default.
- W2179662562 cites W2175342091 @default.
- W2179662562 doi "https://doi.org/10.1136/gutjnl-2015-310978" @default.
- W2179662562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26611231" @default.
- W2179662562 hasPublicationYear "2015" @default.
- W2179662562 type Work @default.
- W2179662562 sameAs 2179662562 @default.
- W2179662562 citedByCount "6" @default.
- W2179662562 countsByYear W21796625622016 @default.
- W2179662562 countsByYear W21796625622017 @default.
- W2179662562 countsByYear W21796625622018 @default.
- W2179662562 countsByYear W21796625622019 @default.
- W2179662562 countsByYear W21796625622020 @default.
- W2179662562 countsByYear W21796625622021 @default.
- W2179662562 crossrefType "journal-article" @default.
- W2179662562 hasAuthorship W2179662562A5056297092 @default.
- W2179662562 hasConcept C159047783 @default.
- W2179662562 hasConcept C159654299 @default.
- W2179662562 hasConcept C203014093 @default.
- W2179662562 hasConcept C2522874641 @default.
- W2179662562 hasConcept C2776029263 @default.
- W2179662562 hasConcept C2777382497 @default.
- W2179662562 hasConcept C3020491458 @default.
- W2179662562 hasConcept C542903549 @default.
- W2179662562 hasConcept C71924100 @default.
- W2179662562 hasConceptScore W2179662562C159047783 @default.
- W2179662562 hasConceptScore W2179662562C159654299 @default.
- W2179662562 hasConceptScore W2179662562C203014093 @default.
- W2179662562 hasConceptScore W2179662562C2522874641 @default.
- W2179662562 hasConceptScore W2179662562C2776029263 @default.
- W2179662562 hasConceptScore W2179662562C2777382497 @default.
- W2179662562 hasConceptScore W2179662562C3020491458 @default.
- W2179662562 hasConceptScore W2179662562C542903549 @default.
- W2179662562 hasConceptScore W2179662562C71924100 @default.
- W2179662562 hasIssue "4" @default.
- W2179662562 hasLocation W21796625621 @default.
- W2179662562 hasLocation W21796625622 @default.
- W2179662562 hasOpenAccess W2179662562 @default.
- W2179662562 hasPrimaryLocation W21796625621 @default.
- W2179662562 hasRelatedWork W1843298502 @default.
- W2179662562 hasRelatedWork W1981361863 @default.
- W2179662562 hasRelatedWork W1989174077 @default.
- W2179662562 hasRelatedWork W2006538744 @default.
- W2179662562 hasRelatedWork W2038043114 @default.
- W2179662562 hasRelatedWork W2070226647 @default.
- W2179662562 hasRelatedWork W2083879052 @default.
- W2179662562 hasRelatedWork W2130435458 @default.
- W2179662562 hasRelatedWork W2361629369 @default.
- W2179662562 hasRelatedWork W3203138030 @default.
- W2179662562 hasVolume "65" @default.
- W2179662562 isParatext "false" @default.
- W2179662562 isRetracted "false" @default.
- W2179662562 magId "2179662562" @default.
- W2179662562 workType "article" @default.